$102 Million is the total value of VHCP Management, LLC's 24 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DBV Technologies | $32,492,000 | +11.6% | 456,893 | 0.0% | 31.95% | +5.9% | ||
| HRTX | Heron Therapeutics Inc | $18,879,000 | -4.5% | 1,095,734 | 0.0% | 18.57% | -9.4% | |
| FLML | Flamel Technologies S.A. | $6,200,000 | +15.5% | 500,000 | 0.0% | 6.10% | +9.6% | |
| ADVM | Adverum Biotechnologies | $4,532,000 | +30.0% | 1,102,735 | 0.0% | 4.46% | +23.4% | |
| BCRX | BioCryst Pharmaceuticals Inc | $4,433,000 | +55.3% | 1,005,104 | 0.0% | 4.36% | +47.4% | |
| LPCN | Lipocine Inc | $3,791,000 | +46.7% | 849,921 | 0.0% | 3.73% | +39.2% | |
| AXGT | Axovant Sciences Ltd | $2,578,000 | +9.1% | 184,110 | 0.0% | 2.54% | +3.5% | |
| ZFGN | Zafgen Inc | $1,993,000 | -44.7% | 602,114 | 0.0% | 1.96% | -47.6% | |
| ASND | Ascendis Pharma A/S | $1,809,000 | +51.5% | 90,000 | 0.0% | 1.78% | +43.8% | |
| BGNE | BeiGene Ltd | $1,571,000 | +3.4% | 51,000 | 0.0% | 1.54% | -1.9% | |
| STML | Stemline Therapeutics Inc | $1,467,000 | +60.0% | 135,420 | 0.0% | 1.44% | +51.9% | |
| EDGE | Edge Therapeutics Inc | $1,405,000 | +2.9% | 135,000 | 0.0% | 1.38% | -2.3% | |
| AKTX | Akari Therapeutics Plc | $1,348,000 | -36.9% | 158,352 | 0.0% | 1.33% | -40.1% | |
| ABIO | ARCA biopharma Inc | $1,309,000 | -2.4% | 462,399 | 0.0% | 1.29% | -7.4% | |
| CTMX | CytomX Therapeutics Inc | $1,007,000 | +53.5% | 64,200 | 0.0% | 0.99% | +45.6% | |
| DNAI | ProNAI Therapeutics Inc | $102,000 | -8.9% | 56,056 | 0.0% | 0.10% | -13.8% | |
| AGLE | Aeglea BioTherapeutics | $38,000 | +31.0% | 6,000 | 0.0% | 0.04% | +23.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DBV Technologies | 14 | Q4 2016 | 33.5% |
| BioCryst Pharmaceuticals Inc | 13 | Q4 2016 | 11.9% |
| Ocera Therapeutics | 13 | Q4 2016 | 4.9% |
| Anacor Pharmaceuticals Inc | 12 | Q1 2016 | 35.6% |
| Heron Therapeutics Inc | 12 | Q4 2016 | 20.5% |
| Flamel Technologies S.A. | 12 | Q4 2016 | 6.1% |
| GW Pharmaceuticals | 11 | Q4 2015 | 19.9% |
| Lipocine Inc | 11 | Q4 2016 | 7.5% |
| Stemline Therapeutics Inc | 11 | Q4 2016 | 1.7% |
| Zafgen Inc | 10 | Q3 2016 | 5.7% |
View VHCP Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2018-02-28 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-14 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-13 |
| 13F-HR | 2016-02-12 |
| 13F-HR | 2015-11-13 |
| 13F-HR | 2015-08-13 |
| 3 | 2015-06-17 |
| 13F-HR | 2015-05-14 |
View VHCP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.